Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas
Leila T. Tchelebi(Northwell Health), Joseph M. Herman(Johns Hopkins University), Michael D. Chuong(Baptist Hospital of Miami), Tyler Zemla(Mayo Clinic), Eugene J. Koay(The University of Texas MD Anderson Cancer Center), Jeffrey A. Meyerhardt(CancerCare), Qian Shi(Mayo Clinic), Eileen M. O’Reilly(Memorial Sloan Kettering Cancer Center), Ardaman Shergill(University of Chicago), Diana Segovia(Mayo Clinic), Koren Smith(University of Massachusetts Chan Medical School), Thomas J. FitzGerald(University of Massachusetts Chan Medical School), Jessica Lowenstein(University of California, San Diego), Matthew H. G. Katz(The University of Texas MD Anderson Cancer Center)
International Journal of Radiation Oncology*Biology*Physics
March 15, 2024
Cited by 31
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k